EUMF Investment of €12.9M in Sanaria Highlighted in BioBuzz Article
On December 2nd, 2020, the European Union Malaria Fund’s (EUMF) investment of €12.9 million in Sanaria Inc. was highlighted in an BioBuzz article written by Alex Keown.
The investment will fund the development of two Malaria vaccines, one Malaria prophylactic, and a SARS-CoV-2 vaccine. Sanaria is the first and only U.S.-based company that has received funding from the EUMF!
The full article can be accessed by this link.
